admin – Page 418 – Get News Story

AmericanCross Staffing App Officially Launches: The First Innovative Platform Connecting Clinics and Therapists Instantly

AmericanCross Staffing Agency announces the official launch of the AmericanCross Staffing App, a healthcare staffing platform designed to connect clinics and licensed therapists through a streamlined and flexible staffing experience.

Built for the rehabilitation industry, the AmericanCross Staffing App supports Physical Therapists (PTs), Occupational Therapists (OTs), Physical Therapist Assistants (PTAs), and Physical Therapy Aides by simplifying the process of finding coverage, managing schedules, and improving communication between clinics and healthcare professionals.

Available on both iOS and Android, the platform offers a digital staffing solution that helps clinics fill shifts more efficiently while giving therapists greater flexibility in managing their schedules.

Supporting the Physical Therapy Workforce

The demand for qualified rehabilitation professionals continues to grow across the United States, creating staffing and scheduling challenges for many clinics and healthcare organizations.

The AmericanCross Staffing App was developed to help address common operational challenges, including staffing gaps, scheduling coordination, and administrative workload.

Through the platform, clinics can:

Send staffing requests digitally
Connect with available therapists in specific areas
Manage schedules and coverage more efficiently
Approve, reject, or request edits for timesheets electronically
Reduce administrative workload and staffing delays

Therapists using the platform can:

Manage availability directly through the app
Block and unblock schedules as needed
Receive job opportunities in preferred locations
Manage shifts and timesheets from mobile devices
Access flexible work opportunities based on their preferences

Supporting Flexibility for Rehabilitation Professionals

The platform is designed to support scheduling flexibility and workforce coordination for rehabilitation professionals and healthcare facilities.

By simplifying staffing communication and scheduling management, the app also assists clinic owners and administrative teams in streamlining day-to-day operations.

Technology Designed for Healthcare Staffing

The AmericanCross Staffing App includes features such as:

Real-time staffing requests
Therapist notifications
Digital shift management
Automated and manual timesheet creation
Therapist and clinic onboarding
Mobile scheduling and communication tools
Multi-location staffing support

The platform was developed with a focus on accessibility and ease of use for both independent therapists and healthcare organizations.

Supporting Continuity of Care

Reliable staffing plays an important role in maintaining continuity of care for patients receiving rehabilitation services. By helping clinics connect with qualified professionals more efficiently, AmericanCross Staffing aims to support smoother staffing coordination within rehabilitation settings.

The AmericanCross Staffing App is now available for download on iOS and Android devices.

iPhone/IOS:

https://apps.apple.com/us/app/americancross/id6763808545

Android:

https://play.google.com/store/apps/details?id=com.americancross.staffing&pcampaignid=web_share

To learn more visit: https://www.americancross.co/

For media inquiries, partnerships, or additional information, visit: Ceo@americancross.co

Media Contact
Company Name: AmericanCross Staffing Agency
Contact Person: Mohamed Desoki – CEO
Email: Send Email
City: Bronx
State: New York
Country: United States
Website: www.americancross.co

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: AmericanCross Staffing App Officially Launches: The First Innovative Platform Connecting Clinics and Therapists Instantly

Asprofin Bank Explores Up to USD 12 Billion Sovereign Data Center Programme Across Three Strategic UAE Sites

Dubai, UAE – As global demand for artificial intelligence infrastructure accelerates at unprecedented speed, Asprofin Bank Corporation has announced it is evaluating a large-scale sovereign data center programme across three strategic sites in the United Arab Emirates. The proposed initiative, developed in collaboration with IDC Technologies and presented for preliminary review to Digital Dubai, represents a feasibility-stage exploration into one of the region’s most ambitious AI infrastructure concepts to date.

The proposed programme envisions 3 hyperscale computing campuses. Together, the sites could deliver between 750 MW and 1,280 MW of sovereign AI computing capacity over a phased development timeline of 10 to 15 years. The estimated investment envelope ranges between USD 5 billion and USD 12 billion, depending on final engineering design, energy configuration, and deployment structure.

While still in feasibility assessment, Asprofin Bank describes the initiative as a strategic response to rapidly expanding global demand for sovereign compute infrastructure, particularly in regions prioritizing data localization, AI sovereignty, and energy-efficient digital ecosystems.

A Project Emerging in the Middle of a Global AI Infrastructure Boom

The announcement comes at a time when global investment in data center infrastructure is entering what analysts describe as a “supercycle.” According to JLL’s 2026 Global Outlook, approximately 100 gigawatts of new data center capacity is expected to be added worldwide between 2026 and 2030, representing an estimated USD 1.2 trillion in infrastructure value creation.

In the United Arab Emirates specifically, market momentum continues to accelerate. Research estimates the UAE data center market will grow from approximately USD 2.38 billion in 2025 to USD 6.7 billion by 2031, driven by a compound annual growth rate of nearly 18.82%. Within that ecosystem, the colocation segment alone is projected to reach USD 1.77 billion by 2026.

Industry conditions remain highly competitive, with vacancy rates across hyperscale facilities continuing to decline as new capacity is frequently pre-leased before construction is completed. This supply-demand imbalance has intensified interest in scalable, energy-efficient, and sovereign-controlled infrastructure models.

A Cost Structure That Challenges Industry Benchmarks

One of the most notable aspects of the Asprofin Bank programme is its proposed cost efficiency model. Conventional hyperscale data center construction in 2026 typically ranges between USD 10 million and USD 12 million per megawatt, while AI-optimized facilities often exceed USD 20 million per megawatt due to higher power density requirements and advanced cooling systems.

By comparison, Asprofin Bank’s internal modelling suggests its nano-scale modular architecture could reduce capital expenditure significantly, targeting an estimated USD 4 million to USD 8 million per megawatt. If achieved, this would represent a potential 30% to 65% reduction compared to current industry benchmarks.

This efficiency gap is attributed to a combination of structural innovations, including prefabricated modular deployment systems, advanced cooling architecture, and high-efficiency energy integration at site level.

The proposed programme also includes a differentiated comparison against large-scale regional initiatives such as the Stargate UAE project, a multi-gigawatt AI campus backed by major global technology and investment partners. While such projects are projected to require significant capital expenditure per megawatt—often exceeding USD 30 million in early phases—Asprofin Bank’s model aims to reduce cost intensity through modular scaling and engineering standardization.

Engineering Model Built on Speed, Efficiency, and Security

The proposed infrastructure architecture is based on three core technical pillars.

First is a nano-scale modular deployment system using containerized computing units capable of delivering up to 500 kW per module. These units are designed for rapid assembly and deployment, potentially reducing construction timelines from the traditional 18–24 months to approximately 8–12 weeks per module.

Second is a proprietary cooling system designed to optimize energy consumption and improve Power Usage Effectiveness (PUE). While global data center averages range between 1.55 and 1.60 according to the Uptime Institute, and hyperscale facilities typically operate between 1.3 and 1.5, Asprofin Bank’s design targets a PUE of 1.15 or lower. If achieved, this would represent a significant reduction in cooling-related energy consumption and long-term operational costs.

Third is a sovereign energy integration model anchored in renewable energy infrastructure. The programme targets more than 80% renewable energy usage, positioning it among the more sustainability-focused AI infrastructure concepts currently under evaluation in the region.

In addition another site is envisioned as a high-security underground facility designed for sovereign workloads, including advanced computing and sensitive data processing. The design concept includes multi-layer structural reinforcement, electromagnetic shielding, and thermally isolated infrastructure zones intended to support critical national applications.

Sovereign Demand Driving Infrastructure Expansion

Asprofin Bank’s feasibility study is also aligned with broader structural demand trends in artificial intelligence and digital sovereignty.

The introduction of updated data protection frameworks in the UAE is expected to increase requirements for in-country storage and processing of sensitive data across financial, healthcare, and government sectors. This regulatory shift is already driving demand for sovereign compute environments that meet both compliance and national security requirements.

At a regional level, technology spending across the Middle East and North Africa is projected to reach USD 169 billion in 2026, according to Gartner. Meanwhile, sovereign wealth funds across the Gulf region allocated an estimated USD 66 billion toward artificial intelligence and digital transformation initiatives in 2025 alone.

Global policy discussions are also reinforcing this trajectory. A 2026 analysis by the World Economic Forum emphasized that AI infrastructure is increasingly being treated as critical national infrastructure, placing data center capacity at the intersection of economic development, digital sovereignty, and national security.

Within this environment, Asprofin Bank positions its proposed programme as a hybrid infrastructure model capable of serving both sovereign and commercial demand. The three-site structure—combining underground secure computing, carrier-neutral connectivity, and renewable-powered hyperscale capacity in the solar park—aims to create a vertically integrated ecosystem for AI workloads.

Strategic Positioning in a Competitive Investment Landscape

The global data center sector continues to attract unprecedented capital inflows. Industry estimates suggest total global data center capital expenditure surged by approximately 57% in 2025, with projections indicating up to USD 3 trillion in cumulative investment requirements by 2030.

Major technology firms are already expanding their regional presence. Microsoft has announced multi-billion-dollar investments in UAE cloud infrastructure, while Oracle has launched its first Middle East OCI Supercluster. These developments indicate sustained demand for large-scale compute capacity across the region.

Asprofin Bank’s proposal enters this landscape as a feasibility-stage exploration focused on capital efficiency, rapid deployment, and sovereign-grade infrastructure design. If developed, the programme could complement existing hyperscaler investments by addressing demand segments requiring higher security classification, energy efficiency optimization, and regulatory compliance.

About Asprofin Bank

Asprofin Bank Corporation is an international financial institution specializing in the structuring, financing, and development of large-scale infrastructure programmes. The current announcement represents an ongoing strategic feasibility exploration and does not constitute a binding commitment, capital allocation, or securities offering.

Media Contact
Company Name: Institutional Communications & Investor Relations
Contact Person: Q. Lin, PR Director
Email: Send Email
City: Dubai
Country: United Arab Emirates
Website: https://www.asprofinbank.org/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asprofin Bank Explores Up to USD 12 Billion Sovereign Data Center Programme Across Three Strategic UAE Sites

Why Professional Support for Company formation consultants in Saudi Arabia Makes All the Difference

Introduction

Many entrepreneurs underestimate the complexity of company formation consultants in Saudi Arabia until they are already in the middle of the process. Government portals, Arabic documentation, multiple ministry approvals, and sector-specific licensing requirements create a landscape that is genuinely difficult to navigate without professional expertise. Businesses that engage expert support for company formation consultants in saudi arabia complete the process faster, with fewer errors, and with significantly better structural and strategic outcomes.

This article explores why professional support transforms company formation consultants in saudi arabia from a stressful, time-consuming ordeal into a smooth, well-structured journey — and how integrating professional accounting and HR services from the very start positions your business for immediate, sustainable operational success in Saudi Arabia.

The Measurable Value of Expert Guidance

Professional advisors who specialize in company formation consultants in saudi arabia bring three critical assets to every engagement: deep regulatory knowledge, established government relationships, and proven process experience. Their understanding of Saudi commercial law, MISA regulations, and sector-specific requirements enables them to identify the optimal path through the setup process for each client’s unique situation and business model.

Their established relationships with government agencies accelerate approvals and help resolve issues that inevitably arise during company formation consultants in saudi arabia. Their documented processes, refined through hundreds of prior engagements, minimize errors and ensure nothing critical is overlooked. For clients, this translates directly into a faster, smoother, and more reliable setup experience with better long-term structural outcomes.

The cost of professional support for company formation consultants in saudi arabia should be viewed as a strategic investment rather than an operating expense. The time saved, errors avoided, and superior structural decisions made during a professionally supported setup generate returns that far exceed the advisory fees paid — often within the first year of operations alone.

Accounting: Compliance and Competitive Intelligence

Professional outsource bookkeeping transforms raw financial data into actionable competitive intelligence. When your accounting function captures every transaction accurately and in real time, management gains the visibility needed to identify market opportunities, respond to competitive challenges, and continuously optimize business performance across all operational dimensions.

Quality outsource bookkeeping also reduces audit risk substantially. ZATCA increasingly uses sophisticated data analytics to identify businesses whose returns appear inconsistent with their industry benchmarks or company size. Professional outsource bookkeeping ensures your filings are accurate, comprehensively supported, and fully defensible under the most rigorous regulatory scrutiny.

HR: The Engine of Organizational Performance

Organizational performance ultimately depends on the quality of your people and the effectiveness of your people processes. Professional outsourced hr solution designs and implements the HR systems that consistently drive high performance: clear job descriptions, competitive and fair compensation, structured onboarding, regular meaningful performance reviews, and targeted development programs aligned with business strategy.

Expert outsourced hr solution also provides the compliance infrastructure needed to operate without significant legal exposure. From employment contract templates that fully comply with Saudi law to disciplinary procedures that protect both employees and the company, professional HR support creates a legally sound, trust-based employment environment that attracts and retains the best available talent.

Conclusion

Investing in professional support for company formation consultants in saudi arabia is one of the highest-return decisions a business owner can make. Combined with the financial discipline of expert outsource bookkeeping and the people expertise of professional outsourced hr solution, your business launches and operates with a level of professionalism that customers, partners, banks, and investors recognize, respect, and value in their counterparties.

Media Contact
Company Name: Motaded
Contact Person: Mukhlid Alqahtani
Email: Send Email
City: Riyadh
Country: Saudi Arabia
Website: https://motaded.com.sa/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Why Professional Support for Company formation consultants in Saudi Arabia Makes All the Difference

Custom Outdoor Vending Machine Unlocks 24/7 Locations for Georgia-Area Operator, VMFS USA Reports

Operator Corey Roew reports $4,000 to $5,000 monthly per machine on a weatherized custom build designed for environments standard vending cannot serve.

MIAMI, FL – May 27th, 2026 – VMFS USA, a Miami-based vending machine supplier and manufacturer, today highlighted the deployment of a custom outdoor-rated vending machine built for operator Corey Roew, an early example of how purpose-built hardware is opening location categories that have historically been inaccessible to the vending industry.

Most vending machines are designed for indoor environments, climate-controlled spaces, breakrooms, lobbies, hallways. Outdoor placements, high-traffic exposed sites that operate 24 hours a day, have remained largely out of reach because standard machines aren’t built to withstand the conditions. Roew approached VMFS asking for an outdoor-rated, weatherized version of one of the company’s core machines. The modifications added approximately 15 percent to his upfront equipment cost.

The custom build unlocked locations Roew could not have served otherwise. He reports monthly revenue of $4,000 to $5,000 per machine on the deployment.

“The conventional wisdom in this industry is that custom builds are a premium you’ll struggle to earn back,” said Jose Perez, Co-founder and CEO of VMFS USA. “Corey’s deployment is the clearest counterexample we have. When the hardware is built for where the demand actually lives, the economics work. That’s the case we make to operators every day, and Corey is the operator who proved it.”

Roew’s deployment reflects a broader direction in VMFS’s product strategy. Alongside its standard machine line, the company offers configurable and custom builds, including outdoor-rated, age-verification, and category-specific units, designed to serve location types and product categories that conventional vending equipment cannot reliably handle.

In addition to its core hardware business, VMFS USA operates three sister companies serving vending operators: VPlaced for location matching between operators and businesses, VAdviced for state-by-state legal compliance, and VMarketed for marketing, web, and SEO services.

About VMFS USA

VMFS USA is a Miami-based vending machine supplier and manufacturer serving operators, businesses, and institutions across the United States. Machines are designed in Miami and manufactured overseas, with nationwide support and configurable options for a range of operator use cases. Founded in 2018, VMFS USA also operates sister companies VPlaced, VAdviced, and VMarketed, providing location matching, legal compliance, and marketing services tailored to the vending industry. Learn more at vmfsusa.com.

Media Contact: Damian Fuentes, VMFS USA, Damian@vmfsusa.com, +1 (305) 395-3997, vmfsusa.com

Media Contact
Company Name: VMFS USA
Contact Person: Damian Fuentes
Email: Send Email
City: Miami
State: Florida
Country: United States
Website: vmfsusa.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Custom Outdoor Vending Machine Unlocks 24/7 Locations for Georgia-Area Operator, VMFS USA Reports

BullRun Releases New Market Analysis on Risks Threatening Current Bull Market Momentum

Every time a bull market has run for a few years, the same conversation starts happening at dinner tables, in trading forums, and on financial television. People start saying things like “this rally is getting old” or “we are overdue for a correction.” The implication is that bull markets have some kind of natural expiration date, that they age and then quietly pass away like a tired animal.

That is completely wrong. And believing it has cost investors billions of dollars in missed returns over the decades.

Bull markets do not die of old age. They get murdered. And the murder weapon is almost always one of the same few things, wielded by one of the same few suspects. If you know what to look for, you can see the threat coming long before the market turns. Maybe not in time to call the exact top, nobody can do that consistently, but early enough to protect yourself and position for what comes next.

Let’s talk about who actually kills bull markets.

Suspect #1: The Central Bank

The Federal Reserve is the most prolific bull market killer in modern financial history. Not because central bankers want to destroy wealth, but because their job requires them to take away the punch bowl just when the party is getting good.

The mechanism is straightforward. The Fed raises interest rates to cool inflation or prevent the economy from overheating. Higher rates increase the cost of borrowing for businesses and consumers. Corporate earnings growth slows because financing costs rise and discretionary spending falls. At the same time, higher rates make risk-free assets like Treasury bonds more attractive relative to stocks, so the valuation premium investors were willing to pay for equities starts to compress.

The result is a market that was previously expanding on multiple fronts, revenue growth, margin expansion, and multiple expansion, suddenly facing pressure on all three simultaneously. That is how you get bear markets that feel sudden even though the warning signs were there for months.

The 2022 bear market is a perfect recent example. The Fed began telegraphing rate hikes early in the year. Markets initially shrugged. Then as the hiking cycle accelerated at a pace nobody had seen since the 1980s, valuations collapsed across the board, particularly in high-multiple growth stocks that had been priced for a zero-rate world. The bull market did not die because the economy collapsed. It was deliberately strangled by monetary policy trying to fight the worst inflation in forty years.

The lesson is simple: always watch the central bank. Not just what they say, but what the bond market is pricing. When short-term rates are rising rapidly and the yield curve is inverting, the murder weapon is already drawn.

Suspect #2: Inflation Running Too Hot

Moderate inflation is actually healthy for bull markets. Companies can raise prices, revenue grows nominally, and assets appreciate. But when inflation runs too hot, it becomes a destroyer of both economic growth and market valuations.

High inflation erodes consumer purchasing power, which eventually feeds through to lower real spending even if nominal sales numbers look acceptable. It forces the central bank to act aggressively, which brings us back to the first suspect. And it creates uncertainty about future earnings that makes investors unwilling to pay premium multiples.

The insidious thing about inflation as a bull market killer is that it often builds slowly and then arrives all at once. The conditions that allow it to persist, loose monetary policy, supply chain constraints, fiscal stimulus, are often the same conditions that supported the bull market in the first place. The very fuel that fed the rally eventually becomes the fire that burns it down.

Commodity prices, particularly oil, are worth watching as an early warning signal. When energy prices rise sharply and stay elevated, they act as a tax on the entire economy. Every business that uses transportation, manufacturing, or energy inputs sees its costs rise, and those costs either compress margins or get passed to consumers and slow demand. Neither outcome is good for stocks.

Suspect #3: A Credit Market Accident

Most equity investors pay very little attention to credit markets. That is a mistake, because the credit market is where systemic risk first appears before it shows up in stock prices.

A credit market accident happens when something breaks in the plumbing of the financial system. A major institution fails or comes close to failing, a previously safe asset class suddenly becomes illiquid, or spreads between risky bonds and safe bonds widen so dramatically that the cost of capital for the entire economy jumps overnight.

The 2008 financial crisis is the textbook example. For months before Lehman Brothers collapsed, credit markets were sending distress signals that equity investors largely ignored. High-yield spreads were blowing out. Interbank lending rates were elevated. The stock market kept making new highs well into 2007 even as these warning signs accumulated.

When the credit accident finally happened, it was not a gradual decline. It was a sudden seizure that froze the financial system and sent equity markets down more than 50% before they found a floor.

Tracking credit spreads is not complicated. The difference between high-yield corporate bond yields and Treasury yields is freely available and updated daily. When that spread is narrow and stable, credit markets are healthy. When it starts widening sharply, something is wrong, and equity markets usually follow within weeks to months.

Suspect #4: Geopolitical Shock

This is the hardest one to predict because by definition it comes from outside the financial system. Wars, pandemics, terrorist attacks, sudden regime changes, trade wars, any of these can deliver a shock to the global economy that disrupts supply chains, spikes uncertainty, and sends investors running to safety.

The COVID crash of early 2020 is the most recent example. One of the strongest bull markets in history went from all-time highs to a 34% decline in 33 days. Not because of anything that was happening in the economy or financial system, but because an external shock of historic proportions suddenly changed every assumption about growth, corporate earnings, and the functioning of normal economic life.

The good news about geopolitical shocks is that their market impact, while severe, tends to be temporary when the underlying economy is healthy. The 2020 crash was followed by one of the fastest recoveries ever seen because the financial plumbing was intact and monetary and fiscal policy responded aggressively. Contrast that with 2008, where the shock came from inside the financial system itself and required years to fully repair.

Suspect #5: Valuation Extremes and Investor Euphoria

This one operates differently from the others because it does not require an external trigger to cause damage. When valuations reach extremes and investor sentiment turns euphoric, the market becomes extremely fragile. It does not take a crisis to start a bear market. It just takes the music stopping.

Euphoria is recognizable if you know what to look for. IPO markets go into overdrive, with companies that have never turned a profit getting valued at billions. Retail investor participation surges. Everyone from cab drivers to relatives who previously had no interest in stocks starts giving tips. Leverage in the system increases as investors borrow to buy assets they believe can only go up.

When valuations are stretched and euphoria is high, the market does not need a reason to fall. It just needs to stop having a reason to rise. The absence of new buyers is enough.

What Indian Investors Need to Watch Specifically

The five suspects above operate in every major market, not just the US. In India, the same dynamics play out through different instruments but with the same underlying logic.

The RBI plays the role of the Fed. When the RBI shifts from an accommodative to a tightening stance, the impact on rate-sensitive sectors like banking, real estate, and NBFCs is immediate and significant. Watching RBI policy decisions and the direction of 10-year G-Sec yields gives Indian investors the same early warning that Fed watchers use in the US.

On the euphoria front, the Indian IPO market is one of the most sensitive real-time barometers of investor sentiment available. When the grey market premium on upcoming listings starts hitting extreme levels across the board, it is a reliable signal that retail enthusiasm has moved into territory that historically precedes a cooldown. Tracking that data consistently is something every serious Indian investor should be doing. The IPO GMP tracker at BullRun gives you a live, updated view of grey market premiums across upcoming listings, so you can see exactly when the enthusiasm thermometer is running dangerously hot.

And when you want to check whether the broader sectoral picture is showing any of the rotation patterns that typically appear when a bull market is aging, the BullRun sector tracker gives you a clean, organized breakdown of where strength and weakness are developing across Indian market sectors right now.

So What Do You Actually Do With This Information?

Understanding who murders bull markets is useful only if it changes how you behave as an investor.

The practical takeaway is to build a watchlist of warning signals and check them regularly. Central bank policy direction, inflation trends, credit spreads, geopolitical developments, and valuation metrics across different sectors all tell you something about where the bull market is in its life cycle.

None of this will let you call the exact top. Nobody can do that. But it will keep you from being the last person to realize the bull market is already over. And in investing, not being the last to know is worth a lot.

The Final Word

Bull markets are not fragile things that collapse under their own weight. They are powerful economic forces that require real weapons to stop them. Central bank tightening, runaway inflation, credit market accidents, geopolitical shocks, and valuation extremes are the weapons. They have been used before and they will be used again.

The investors who understand this are not constantly bearish and scared. They are the opposite. They ride bull markets aggressively because they know what to watch for. They know that as long as the murder weapons are safely holstered, the rally has room to run.

And they know that when those weapons start to appear, it is time to pay very close attention.

Media Contact
Company Name: BullRun
Contact Person: AI Stock Screener
Email: Send Email
Country: India
Website: https://www.bullrun.co.in/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: BullRun Releases New Market Analysis on Risks Threatening Current Bull Market Momentum

Congressional Candidate Peter Roybal Calls for Accountability, Community Rebuilding, and Leadership Renewal

Congressional candidate Peter Roybal called for greater accountability and leadership transparency during a Los Angeles press conference while also announcing The Committee of Fire Heroes, a coalition focused on rebuilding communities impacted by the Eaton Fire and supporting long term recovery efforts.

2026 – Congressional candidate and CEO of Pow Wow on Parade, Peter Roybal, held a press conference in front of the Edward R. Roybal Federal Building calling for the immediate resignation of Congresswoman Judy Chu over what he described as longstanding political associations connected to individuals arrested in federal investigations involving alleged Chinese influence operations.

Roybal referenced the conviction of former Arcadia Mayor Eileen Wang and co-defendant Yaoning Sunin a federal case involving their arrests and sentencing for espionage connected to China. He also referenced widely reported concerns surrounding Christine Fang, also known as “Fang Fang,” who was previously linked to former Congressman Eric Swalwell in reports concerning Chinese intelligence outreach efforts.

Roybal stated these controversies raise serious questions about political judgment, accountability, and national security, and he called for greater transparency from elected officials connected to individuals involved in such investigations.

A longtime figure in the San Gabriel Valley community, Roybal is also recognized as part of the “Brown Kennedys,” a name associated with a legacy of public service. His family ties include Congressman Edward R. Roybal and Lucille Roybal-Allard, both of whom served the community and represented the28th Congressional District for decades.

During the event, Roybal also announced the formation of The Committee of Fire Heroes, a coalition offire victims and community advocates committed to rebuilding neighborhoods impacted by the Eaton Fire and seeking accountability regarding relief and recovery funding raised on behalf of victims.

According to Roybal, members of the committee were selected for their dedication, resilience, and commitment to ensuring long-term recovery efforts for survivors and the broader community.

“As the Brown Kennedys, our goal is to bring hope, pride, and restore Camelot back to Altadena,” Roybal said. “Our community deserves leadership rooted in service, courage, and accountability.”

Roybal described his campaign as grounded in a multigenerational legacy of public service,perseverance, and Native American heritage, emphasizing who better to save America and Altadenathan “Thee” Native American.

Connect: http://Powwowonparade.org

Media Contact
Company Name: C2PRMedia
Contact Person: Cynthia Latson
Email: Send Email
Phone: 888-275-5152 EXT 808
City: Los Angeles
State: CA
Country: United States
Website: www.iconnectyou.today

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congressional Candidate Peter Roybal Calls for Accountability, Community Rebuilding, and Leadership Renewal

Opioid Use Disorder Therapeutics Pipeline Strengthens as 10+ Biopharma Companies Advance Targeted Treatment Strategies | DelveInsight

DelveInsight’s “Opioid Use Disorder Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Opioid Use Disorder pipeline landscape. It covers the Opioid Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Opioid Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Opioid Use Disorder Pipeline? @ https://www.delveinsight.com/sample-request/opioid-related-disorder-pipeline-insight

Key Takeaways from the Opioid Use Disorder Pipeline Report

On May 22, 2026- Eli Lilly and Company conducted a phase 2 study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.
On May 15, 2026- Merck Sharp & Dohme LLC initiated a phase 3 study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
In March 2026- Sonara Health initiated a Phase II of this SBIR aims to compare Sonara against usual take-homes to assess its impact on retention in care, opioid use, patient outcomes, and costs of care.
In March 2026- Indivior Inc. announced a study will evaluate the pharmacokinetics (PK), safety, and tolerability of INDV-6001 following multiple doses in participants with OUD to select optimum dosing regimens for future studies. Prior to receiving INDV-6001, participants will be stabilised on 12-16 mg of transmucosal (TM) BUP (SUBOXONE®) or will transition from a 100-mg monthly maintenance dose of SC extended-release BUP (SUBLOCADE®). This study will also evaluate the use of alternative injection sites (thigh, back of upper arm), which may be desirable in this patient population for the anticipated extended durations of treatment.
In March 2026- Merck Sharp & Dohme LLC conducted a phase 3 study is to learn about the safety of suvorexant and how well people tolerate it. Researchers also want to learn if suvorexant helps people sleep longer compared to people who take placebo. A placebo looks like the study medicine but has no actual study medicine in it.
DelveInsight’s Opioid Use Disorder Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Opioid Use Disorder treatment.
The leading Opioid Use Disorder Companies, such as GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
Promising Opioid Use Disorder Therapies such as XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM203, and others.

Want to know which companies are leading innovation in Opioid Use Disorder? @ Opioid Use Disorder Clinical Trials Assessment

The Opioid Use Disorder Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Opioid Use Disorder Pipeline Report also highlights the unmet needs with respect to the Opioid Use Disorder.

Opioid Use Disorder Overview

Opioids are a class of drugs that bind with the opioid receptor present on the central nervous system in the brain and body to reduce the sensation of pain. Opioids predominantly include prescription pain relievers, synthetic opioids, and heroines. Although opioids reduce the perception of pain but chronic use of opioids can cause distress and impairment. Opioid Related Disorder includes overpowering desire to use opioids, dependence, increased opioid tolerance, and addictions which represents the most severe form of the disorders. When discontinued, the individual suffers from withdrawal syndrome.

Opioid Use Disorder Emerging Drugs Profile

ASP8062: Astellas Pharma

Astellas Pharma’s lead drug candidate, ASP8062, is an analgesic class drug. It is an orally active γ-amino-butyric acid type B (GABAB) receptor positive allosteric modulator currently in phase II development. Phase 2 data demonstrated that ASP8062 for the treatment of Opioid Related Disorder as well as pain has beneficial effects. It was safe and well tolerated by the healthy subjects. It enhances the GABAergic transmission mediated by GABAB receptors by increasing the potency of endogenous agonist without overstimulating the receptor.

OPNT-003 (Intranasal Nalmefene): Opiant Pharmaceuticals

Opiant Pharmaceuticals “breakthrough” drug OPNT-003 is a long lasting opioid antagonist for the treatment of Opioid overdose and has demonstrated positive data from its phase I trials.

If you’re tracking ongoing Opioid Use Disorder Clinical trials @ Opioid Use Disorder Treatment Drugs

The Opioid Use Disorder Pipeline report provides insights into:-

The report provides detailed insights about companies that are developing therapies for the treatment of Opioid Use Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Opioid Use Disorder Treatment.
Opioid Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Opioid Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Opioid Use Disorder market.

Opioid Use Disorder Companies

GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others

Opioid Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous
Intravenous
Oral
Intramuscular
Molecule Type

Opioid Use Disorder Products have been categorized under various Molecule types such as

Small molecules
Natural metabolites
Monoclonal antibodies
Product Type

From emerging drug candidates to competitive intelligence, the Opioid Use Disorder Pipeline Report @ Opioid Use Disorder Market Drivers and Barriers, and Future Perspectives

Scope of the Opioid Use Disorder Pipeline Report

Coverage- Global
Opioid Use Disorder Companies- GW Pharmaceuticals, Opiant Pharmaceuticals, Trevi Therapeutics, Aphios, Astellas Pharma, and others.
Promising Opioid Use Disorder Therapies- XR-NTX, Methadone, Buprenorphine (BUP), INDV-2000, Lofexidine 0.18 MG, NTX/BUP, Naltrexone, CAM2038 and others.
Opioid Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Opioid Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Opioid Use Disorder Treatment landscape in this detailed analysis @ Opioid Use Disorder Emerging Drugs and Major Players

Table of Contents

Introduction
Executive Summary
Opioid Related Disorder: Overview
Pipeline Therapeutics
Therapeutic Assessment
Opioid Related Disorder – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Opioid Related Disorder Collaboration Deals
Mid Stage Products (Phase II)
ASP8062: Astellas Pharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OPNT-003: Opiant Pharmaceuticals
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report…..
Inactive Products
Opioid Related Disorder Key Companies
Opioid Related Disorder Key Products
Opioid Related Disorder- Unmet Needs
Opioid Related Disorder- Market Drivers and Barriers
Opioid Related Disorder- Future Perspectives and Conclusion
Opioid Related Disorder Analyst Views
Opioid Related Disorder Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/opioid-related-disorder-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Opioid Use Disorder Therapeutics Pipeline Strengthens as 10+ Biopharma Companies Advance Targeted Treatment Strategies | DelveInsight

Bronchiectasis Clinical Pipeline Demonstrates Strong Growth Backed by 15+ Active Industry Players | DelveInsight

DelveInsight’s, “Bronchiectasis Pipeline Insight 2026” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Bronchiectasis pipeline landscape. It covers the Bronchiectasis pipeline drug profiles, including Bronchiectasis clinical trials and nonclinical stage products. It also covers the Bronchiectasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Bronchiectasis Pipeline @ https://www.delveinsight.com/sample-request/bronchiectasis-pipeline-insight

Key Takeaways from Bronchiectasis Pipeline Report

On May 13, 2026- Boehringer Ingelheim initiated a phase III study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis. Participants are put into 2 groups randomly, which means by chance. One group takes BI 1291583 tablets and the other group takes placebo tablets. A placebo tablet looks like the BI 1291583 tablet but does not contain any medicine. Participants take 1 tablet once a day for up to 1 year and 6 months.
On May 13, 2026- Sanofi conducted a phase2a study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
On May 13, 2026- Verona Pharma Inc. announced a phase II study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer over at least 24 weeks, compared to placebo, in subjects with non-cystic fibrosis bronchiectasis (NCFBE).
DelveInsight’s Bronchiectasis Pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Bronchiectasis treatment.
The leading Bronchiectasis Companies such as AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
Promising Bronchiectasis Pipeline Therapies such as Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Bronchiectasis Treatment Drugs

The Bronchiectasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Bronchiectasis Pipeline Report also highlights the unmet needs with respect to the Bronchiectasis.

Bronchiectasis Overview

Bronchiectasis is an irreversible widening (dilation) of portions of the breathing tubes or airways (bronchi) resulting from damage to the airway wall. The most common cause is severe or repeated respiratory infections, often in people who have an underlying problem with their lungs or immune system.Most people develop a chronic cough, and some also cough up blood and have chest pain and recurrent episodes of pneumonia. Chest x-rays, computed tomography, and breathing tests are usually done to determine the extent and severity of the disorder.

Bronchiectasis Emerging Drugs Profile

Benralizumab: AstraZeneca

Benralizumab is a monoclonal antibody used to treat eosinophilic asthma. Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils and basophils. Currently, being evaluated in Phase III stage of clinical trial evaluation to treat Non-cystic Fibrosis Bronchiectasis.

S1226: SolAeroMed

S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient’s constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways.The rescue treatment works on both physiological and biophysical principles offering a unique approach to relieving airway obstruction. CO2 is a potent, but short acting bronchial smooth muscle relaxant. Perflubron is a non-toxic (biocompatible) medical perfluorocarbon with mucolytic and surfactant properties that acts synergistically with CO2 to provide a much greater and more prolonged broncho-dilatory effect. The drug product is hypothesized to open constricted airways through at least three distinct mechanisms. Firstly, through the relaxant effect of CO2 (alone and dissolved into perflubron) on constricted airway smooth muscle; secondly, by lowering surface tension in the inflamed airways; and finally by possibly facilitating penetration and lubrication of mucus plugs, thus enhancing mucociliary clearance. Furthermore it works by an entirely different mechanism to the ß-adrenergic agonists and thus complements, rather than replaces, existing treatments.

Brensocatib: Insmed

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs.

Explore groundbreaking therapies and clinical trials in the Bronchiectasis Pipeline @ New Bronchiectasis Drugs

The Bronchiectasis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Bronchiectasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bronchiectasis Treatment.
Bronchiectasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bronchiectasis market

Pulmonary Fibrosis Companies

AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.

Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Inhalation
Inhalation/Intravenous/Oral
Intranasal
Intravenous
Intravenous/ Subcutaneous
NA
Oral
Oral/intranasal/subcutaneous
Parenteral
Subcutaneous

Bronchiectasis Products have been categorized under various Molecule types such as

Antibody
Antisense oligonucleotides
Immunotherapy
Monoclonal antibody
Peptides
Protein
Recombinant protein
Small molecule
Stem Cell
Vaccine

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Bronchiectasis Market Drivers and Barriers

Scope of the Bronchiectasis Pipeline Report

Coverage- Global
Bronchiectasis Companies- AstraZeneca, Insmed Incorporated, SolAeroMed, Boehringer Ingelheim, CSL Behring, Thirty Respiratory Limited, RedHill Biopharma Limited, Chiesi Farmaceutici S.p.A., Armata Pharmaceuticals, Alaxia, Parion Sciences, Santhera Pharmaceuticals, Zambon S.p.A. and others.
Bronchiectasis Pipeline Therapies- Clofazimine Inhalation Suspensio, Ambroxol hydrochloride 30 mg, N-acetylcysteine (NAC) 600 mg, AG1321001 (drug), EZ-2053, GDC-6988, RSS0343 Tabella and others.
Bronchiectasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Bronchiectasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Bronchiectasis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Bronchiectasis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Bronchiectasis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Bronchiectasis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Benralizumab: AstraZeneca
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
S1226: SolAeroMed
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
CSL787: CSL Behring
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
AP-PA02: Armata Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Bronchiectasis Key Companies
Bronchiectasis Key Products
Bronchiectasis- Unmet Needs
Bronchiectasis- Market Drivers and Barriers
Bronchiectasis- Future Perspectives and Conclusion
Bronchiectasis Analyst Views
Bronchiectasis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchiectasis Clinical Pipeline Demonstrates Strong Growth Backed by 15+ Active Industry Players | DelveInsight

Multiple Sclerosis Treatment Pipeline Witnesses Strong Innovation with 75+ Companies Advancing Novel Therapeutics | DelveInsight

DelveInsight’s “Multiple Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Multiple Sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Multiple Sclerosis Pipeline @ https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight

Key Takeaways from the Multiple Sclerosis Pipeline Report

On May 19, 2026- Novartis Pharmaceuticals initiated a phase IV study in which breastfeeding mothers treated with ofatumumab and their babies are taking part for up to 1 year. The study consists of a Core Part and a Safety Follow-up Part. The Core Part includes a Screening period and a Sampling period. During the Screening period (up to 4 weeks), the study doctor will assess if mothers can join the study. The Sampling period, during which milk samples and a blood sample will be collected, will last for up to 12 weeks. The Safety Follow-up Part will last for about 9 months, to follow up on health and safety of mothers and their babies.
On May 15, 2026- Sanofi conducted a phase 3 study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with MS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria.
DelveInsight’s Multiple Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Multiple Sclerosis treatment.
The leading Multiple Sclerosis Companies such as Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.
Promising Multiple Sclerosis Therapies such as 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.

Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Multiple Sclerosis Treatment Drugs

The Multiple Sclerosis Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Multiple Sclerosis Pipeline Report also highlights the unmet needs with respect to the Multiple Sclerosis.

Multiple Sclerosis Overview

Multiple Sclerosis is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. MS attacks the axons of the central nervous system, which are protected by myelin, commonly known as white matter. Relapsing–remitting MS: the most common form, affecting about 85% of MS patients. It is marked by flare-ups (relapses or exacerbations) of symptoms followed by periods of remission, when symptoms improve or disappear.

Multiple Sclerosis Emerging Drugs Profile

IMU-838: Immunic Therapeutics

Vidofludimus calcium (IMU-838) is a small molecule investigational drug under development as an oral tablet formulation for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. Bolstered by excellent clinical data from the phase II EMPhASIS trial, Immunic believed that vidofludimus calcium has the potential to demonstrate medically important advantages compared with other treatments, particularly for the early treatment of RMS patients, due to its placebo like safety profile and its robust anti-inflammatory and neuroprotective properties.

BIIB091: Biogen

BIIB091 selectively inhibits Burton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)). Preclinical studies demonstrated BIB091 to be a high potency molecule with good drug-like properties and a safety/tolerability profile suitable for clinical development as a highly selective, reversible BTKi for treating autoimmune diseases such as MS. Currently, the drug is in the Phase II stage of its development for the treatment of Multiple sclerosis.

IMCY-0141: ImCyse

IMCY-0141 is the Company’s second clinical-stage compound. This Imotope is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of Multiple Sclerosis by stopping the body’s immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of multiple sclerosis.

CC-97540: Bristol-Myers Squibb

CC-97540 is an investigational drug developed by Bristol-Myers Squibb, designed as a selective, orally bioavailable tyrosine kinase 2 (TYK2) inhibitor. TYK2 is a member of the Janus kinase (JAK) family involved in the signaling pathways of several pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and type I interferons, which are implicated in autoimmune and inflammatory diseases. By selectively inhibiting TYK2 without significantly affecting other JAK isoforms, CC-97540 aims to reduce inflammation with potentially fewer side effects compared to broader JAK inhibitors. It is being evaluated for use in conditions such as psoriasis and systemic lupus erythematosus. Currently, the drug is in Phase I stage of its clinical trial for the treatment of multiple sclerosis.

Explore groundbreaking therapies and clinical trials in the Multiple Sclerosis Pipeline @ New Multiple Sclerosis Treatment Drugs

The Multiple Sclerosis Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market

Multiple Sclerosis Companies

Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.

The Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Multiple Sclerosis Products have been categorized under various Molecule types such as,

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Multiple Sclerosis Market Drivers and Barriers

Scope of the Multiple Sclerosis Pipeline Report

Coverage- Global
Multiple Sclerosis Companies- Novartis, Sanofi, Immunic, Biocad, Apimeds, Genentech (Roche), Merck, AB Science, Apurano Pharmaceuticals, Biogen, Tiziana Life Sciences, Worg Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio Technology Co., Ltd., ImCyse and others.
Multiple Sclerosis Therapies- 11C-BMS-986196, ofatumumab, Fingolimod, Siponimod, elezanumab, Alemtuzumab, Tecfidera, and others.
Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight’s in-depth pipeline report today! @ Multiple Sclerosis Companies, Key Products and Unmet Needs

Table of Contents

Introduction
Executive Summary
Multiple sclerosis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Multiple sclerosis – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
IMU-838: Immunic Therapeutics
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
BIIB091: Biogen
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
NeuroVax: Immune Response BioPharma
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Multiple sclerosis Key Companies
Multiple sclerosis Key Products
Multiple sclerosis- Unmet Needs
Multiple sclerosis- Market Drivers and Barriers
Multiple sclerosis- Future Perspectives and Conclusion
Multiple sclerosis Analyst Views
Multiple sclerosis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Treatment Pipeline Witnesses Strong Innovation with 75+ Companies Advancing Novel Therapeutics | DelveInsight

Graves’ Disease Therapeutics Market Size (7MM) was ~USD 4,400 million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight

DelveInsight’s “Graves’ Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Graves’ Disease, historical and forecasted epidemiology as well as the Graves’ Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Explore Graves’ Disease Market Trends, treatment landscapes, and emerging therapies shaping the future @ https://www.delveinsight.com/sample-request/graves-disease-market

Key Takeaways from the Graves’ Disease Market Report

On May 26, 2026, Amgen initiated a clinical trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial (NCT06401044).
On May 22, 2026- Viridian Therapeutics Inc. announced a study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), controlled study that will include participants with TED of any duration. The key objectives of this study are to determine if VRDN-003 is safe and tolerable when administered as a series of subcutaneous (SC) injections every 4 weeks or every 8 weeks in participants with TED.
On May 22, 2026- Sanofi conducted a Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves’ disease, with and without Graves’ orbitopathy, aged 18 years or older.
On May 22, 2026- Immunovant Sciences GmbH initiated a Phase 2b study to assess the efficacy, safety, and tolerability of IMVT-1402 in adult participants with Graves’ disease (GD) who are hyperthyroid despite antithyroid drug (ATD) treatment.
Among the 7MM, the US accounted for approximately 48%, EU4 and the UK for 46%, and Japan for 6% of the total prevalent cases of Graves’ disease in 2023.
As per the DelveInsight estimates, it has been found that there were approximately 3,720,200 diagnosed prevalent cases of Graves’ disease in the 7MM in 2023.
In 2023, the manifestation of Graves’ disease in the US showed that Graves’ Ophthalmopathy captured the highest number of cases, i.e., approximately 584,400 cases.
In 2023, the gender-specific diagnosed prevalent cases of Graves’ disease in Japan were approximately 80,450 cases for males and approximately 321,800 cases for females.
The leading Graves’ Disease Companies such as Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.
Promising Graves’ Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

Discover which therapies are expected to grab the Graves’ Disease Market Share @ Graves’ Disease Treatment Market

Graves’ Disease Overview

Graves’ disease is an autoimmune disorder and the most common cause of hyperthyroidism, characterized by the overproduction of thyroid hormones due to the presence of thyroid-stimulating immunoglobulins that activate the thyroid-stimulating hormone (TSH) receptor. This excessive hormone secretion leads to a hypermetabolic state, resulting in symptoms such as weight loss, heat intolerance, palpitations, anxiety, tremors, and fatigue, along with a diffusely enlarged thyroid gland (goiter).

Graves’ Disease Epidemiology Segmentation in the 7MM

Total Prevalent Cases of Graves’ Disease
Total Diagnosed Prevalent Cases of Graves’ Disease
Gender-specific Cases of Graves’ Disease
Graves’ Disease Cases by Manifestations

Download the report to understand which factors are driving Graves’ Disease epidemiology trends @ Graves’ Disease Prevalence

Graves’ Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves’ Disease market or expected to get launched during the study period. The analysis covers Graves’ Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Graves’ Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves’ Disease Therapies and Companies

• Sling Therapeutics, Inc.: linsitinib

• Immunovant Sciences GmbH: Batoclimab

• Amgen: Teprotumumab

• Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg

• Hoffmann-La Roche: Satralizumab

Graves’ Disease Market Outlook

There are three main treatments for Graves’ disease: ATD medications, thyroidectomy, and radioactive iodine therapy. ATD medications prevent the biosynthesis of the thyroid hormone by blocking iodide, the salted or reduced form of iodine, from interacting with thyroglobulin, thus diminishing the amount of hormone produced. Methimazole is the most widely used ATD medication, with a long half-life and low side effects. Another is carbimazole has been approved in European countries but is not approved in the United States. It is an inactive drug that is metabolized in the blood into the active methimazole thus it is less potent. And the last is propylthiouracil, which is the least potent of the available antithyroid medications. Approved in the United States and Europe, propylthiouracil is the initial treatment choice during the first trimester of pregnancy because of the low placental transfer. Propylthiouracil was, for many years, the first-choice ATD in both the USA and South America. But now the American Thyroid Association (ATA) recommends Methimazole over Propylthiouracil. Methimazole is used in most European countries and Japan, whereas carbimazole is mainly used in the UK.

Marketed Graves’ disease Drugs

• TEPEZZA (Teprotumumab-Trbw): Amgen (Horizon Therapeutics)

Teprotumumab, an insulin-like Growth Factor-1 receptor (IGF-1R) inhibitor, is a fully human IgG1 monoclonal antibody produced in Chinese hamster (CHO-DG44) cells with a molecular weight of approximately 148 KD. In January 2020, the US FDA approved TEPEZZA for the treatment of TED after an accelerated Priority Review. And recently, in September 2024, the drug was approved by Japan’s Ministry of Health, Labour, and Welfare (MHLW) for the treatment of active Graves’ orbitopathy. Additionally, in April 2024, Amgen announced its plans to submit a Marketing Authorization Application (MAA) for teprotumumab to the European Medicines Agency (EMA) in the near future. TEPEZZA is currently under investigation in Phase III clinical trials for patients with moderate-to-severe active Graves’ orbitopathy as well as those with chronic TED characterized by a low Clinical Activity Score (CAS). Additionally, Amgen is exploring its potential for subcutaneous administration.

Get In-Depth Knowledge on Acute on Graves’ disease Market Trends and Forecasts with DelveInsight @ Graves’ disease Market Drivers and Barriers

Emerging Graves’ disease Drugs

• IMVT-1401 (batoclimab, RVT-1401): Immunovant, Samsung Biologics, HanAll Biopharma, and Roivant Sciences

Immunovant’s first investigational product, batoclimab (IMVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal FcRn. In nonclinical studies and clinical trials, batoclimab has been observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases, and, as a result, this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered SC injection. Currently, batoclimab is being developed as a low-volume SC injection for the treatment of a variety of IgG-mediated autoimmune disorders, including myasthenia gravis, TED, chronic inflammatory demyelinating polyneuropathy, and Graves’ disease. The drug is currently in Phase III developmental stage. Recently, in September 2024, Immunovant received Investigational New Drug (IND) clearance from the US FDA for IMVT-1402 in Graves’ disease patients who remain hyperthyroid despite treatment with antithyroid drugs. Furthermore, Immunovant plans to initiate clinical trials of IMVT-1402 in a total of ten indications by March 2026.

• VRDN-001 (veligrotug): Viridian Therapeutics

Viridian’s lead product candidate, VRDN-001, is a differentiated monoclonal antibody targeting Insulin-like Growth Factor-1 Receptor (IGF-1R), a clinically and commercially validated target for the treatment of Graves’ ophthalmopathy. In preclinical studies, VRDN-001 had shown to be a full antagonist of IGF-1R, with complete receptor blockade than other anti-IGF-1R antibodies, including the only approved Graves’ Ophthalmopathy therapy. Currently, the drug is currently being evaluated in various Phase III trials for the treatment of Graves’ ophthalmopathy. According to a corporate presentation published in November 2024, the potential PDUFA date and launch of veligrotug are expected in 2H 2026.

Scope of the Graves’ Disease Market Report

• Coverage: 7MM

• Study Period: 2020-2034

• Graves’ Disease Companies- Amgen (Horizon Therapeutics), Immunovant, Samsung Biologics, HanAll Biopharma, Roivant Sciences, Viridian Therapeutics, Argenx, Hoffmann-La Roche, Sling Therapeutics, Tourmaline Bio, Lassen Therapeutics, ACELYRIN and others.

• Graves’ Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.

• Graves’ Disease Therapeutic Assessment: Graves’ Disease current marketed and Graves’ Disease emerging therapies

• Graves’ Disease Market Dynamics: Graves’ Disease market drivers and Graves’ Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Graves’ Disease Unmet Needs, KOL’s views, Analyst’s views, Graves’ Disease Market Access and Reimbursement

Discover more about Graves’ Disease Drugs in development @ Graves’ Disease Ongoing Clinical Trials

Table of Contents

1. Graves’ Disease Market Report Introduction

2. Executive Summary for Graves’ Disease

3. SWOT analysis of Graves’ Disease

4. Graves’ Disease Patient Share (%) Overview at a Glance

5. Graves’ Disease Market Overview at a Glance

6. Graves’ Disease Disease Background and Overview

7. Graves’ Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves’ Disease

9. Graves’ Disease Current Treatment and Medical Practices

10. Graves’ Disease Unmet Needs

11. Graves’ Disease Emerging Therapies

12. Graves’ Disease Market Outlook

13. Country-Wise Graves’ Disease Market Analysis (2020-2034)

14. Graves’ Disease Market Access and Reimbursement of Therapies

15. Graves’ Disease Market Drivers

16. Graves’ Disease Market Barriers

17. Graves’ Disease Appendix

18. Graves’ Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves’ Disease Therapeutics Market Size (7MM) was ~USD 4,400 million in 2023 and is projected to grow at a significant CAGR by 2034, estimates DelveInsight